Biogen Inc.: Health Canada Grants Authorization for LEQEMBI
Health Canada has issued a Notice of Compliance with Conditions for LEQEMBI (lecanemab) for the treatment of early Alzheimer's Disease.
Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI is authorized for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
LEQEMBI targets an underlying cause of the disease and is the first treatment for early AD to be authorized in Canada.
LEQEMBI is for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Authorized by Health Canada
- For adult patients with early Alzheimer's Disease
- Targets an underlying cause of the disease
Author's summary: Biogen Inc. announces Health Canada's authorization of LEQEMBI for early Alzheimer's treatment.
More News
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Acres.com to collaborate with UA System’s Fryar Center - Talk Business & Politics
- Hospital redevelopment: what the first year of construction will look like
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Tonight’s ‘Sports Equinox’ will showcase games throughout the NFL, MLB, NBA and NHL
- Battlefield 6 REDSEC battle royale to officially launch soon
- SEI Study Analyzes Applicability of Security and Zero Trust Principles to Weapon Systems
- Rolls-Royce tests first high-speed methanol marine engine
- Man Utd Failed With £50 Million Mbeumo Alternative
- Why Every Venue Needs Its Own ‘Black Box’ for Public Safety